Stem-like Cells Associated Antigens Augment the Effect of Dendritic Cells-Based Vaccination Against Human Malignant Glioma Cells in Vitro
HUA Wei,YAO Yu,ZHOU Liang-fu,MAO Ying,XIAO Bao-guo,CHU Yi-wei,XU Feng,ZHU Jian-hong
DOI: https://doi.org/10.3760/cma.j.issn.1001-2346.2009.09.034
2009-01-01
Abstract:Objective To compare the different effects between DC-based vaccine implused by tumor stem-like cells (TSCs) and non-TSCs on cytotoxicity in vitro. Method Malignant glioma cell lines(SHG62, SHG66, U87) were cultured in serum contained medium(SCM, DMEM with 10% FBS) or in serum free medium (SFM, DMEM/F12 supplemented with EGF/bFGF)respectively. Clone formation was observed by limiting dilution analysis. Tumor lysates were extracted from cells cultured in the two different mediums after three freeze-thaw cycles. Corresponsive DCs from PBMCs were co-cultured in RPMI1640 with GM-CSF and IL-4, and then matured by tumor lysates to stimulate autologous T cells. HLA-A, HLA -DR,CD80, CD86 of DCs before and after maturation were checked by flowcytometry, and effector cells were checked with CD3,CD16 and CD56. Then effector cells and targeted cells were cocuhured with different ratio and cytotoxicity was investigated on scintillater after impregnation with thymidine labeled with tritium. Results Cells cultured in the two mediums displayed different morphology. The cells in SFM had the ability of better self-renewal. DCs were successfully matured by tumor stem - like associated antigens. Flowcytometric analysis determined that HLA-A, HLA-DR, CD80, CD86 of DCs were up- regulated, and CD3+T cell ratio was significantly improved after co-cultured with corresponsive DCs (P <0.01). Effect cells loaded with tumor stem-like cells associated antigens killed (70.2±5.13)% of non stem-like cells and (56.7±7.81) % of stem-like cells (P<0.001), however effector cells loaded with non stem-like cells associated antigens eliminated only (36.6±6.45) % of non stem-like cells and (9.05±3.49) % of stem-like cells (P<0.001). Conclusions The glioma cells in SFM had better proliferation, and DCs implused by tumor stem-like cells associated antigens augment the protection against malignant glioma cells in vitro, providing robust implications for clinical trials based on DC vaccination.